Global Leukemia Therapeutic Market Research and Forecast 2018-2023

  • ID: 3821023
  • Report
  • Region: Global
  • Orion Market Research Private Limited
20 % OFF
until Mar 31st 2019
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astellas
  • Celgene
  • Eisai
  • Innate Pharma
  • Novartis
  • MORE
Global leukemia market is expected to grow significantly at a CAGR of 8.9% during 2018-2023. Leukemia is a chronic disease which is prevalent across the globe and has been putting economic burden across the globe. It has a considerable presence in developed and developing economies such as US, UK, Spain, China, India, and Korea. The market is expected to perform significantly due to advancement in leukemia therapeutics, R&D, funding from government and private players and successful clinical trials. Untapped APAC region is the most emerging market growing at highest CAGR during the forecast period. However, the high cost of leukemia therapeutic and less awareness among key regions is a concern for the growth of the leukemia therapeutics market in emerging economies. The diagnosis of leukemia includes health and physical exam, Complete Blood Count, Biopsy and Bone Marrow Aspiration, Blood Chemistry Test, Cytochemistry, CT scan, X-ray, MRI, Ultrasound and so on. Leukemia is the growing market the key therapies of leukemia therapeutics include chemotherapy, stem cell transplant, radiation therapy, targeted therapy, watchful waiting, and supportive therapy

The regional outlook of global leukemia therapeutics market includes North America, Europe, APAC, and Rest of the world. North America is further analyzed as the US and Canada; Europe as the UK, Germany, Italy, Spain, and ROE; and APAC as India, China, Japan, and ROAPAC. North America and Europe generate the highest revenues across the globe due to a huge number of leukemia patients and the highest rate of health care spending. APAC region such as China, India, Japan, and Korea is predicted to offer a variety of opportunities for the leukemia market due to improved healthcare spending, infrastructure, and favorable government policies.

Leukemia market players that are profiled in the report include Clavis Pharma ASA, Pfizer, Ambit, Novartis, Bristol, Genzyme, Celgene Cephalon and Innate Pharma. Leukemia market has a huge opportunity for the new entrants and established players since the FDA nod to recent leukemia drugs created massive demand for leukemia drugs. Leukemia market players have a significant investment in R&D programs across the globe. The successful clinical trials of leukemia drugs are expected to get FDA approval in near future. The report also covers various factors that influence the market, for example, the government regulations, drug and device laws and regulations, regulations on clinical trials and government policies are also covered at length. The report also covers the type of Leukemia diagnosis, types and therapies extensively with the latest update on pipeline products in pipeline analysis.

Research Methods and Tools

The market study of leukemia therapeutics has been incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include
  • Financial/annual reports of companies involved in the market
  • Forward-looking statement of key leukemia therapeutics market players
  • Authentic Public Databases
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.
The report is intended for global leukemia therapeutics market players, potential entrants, diagnostic laboratories, healthcare provider, universities for overall market insights. The report provides an in-depth analysis of pricing, market size, market determinants, and the competitive landscape. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis delivering insights into the market for better business decisions.

The Report Covers
  • Comprehensive research methodology of global leukemia therapeutics market.
  • This report also includes a detailed and extensive market overview with Analyst insights & key market trends.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global leukemia therapeutics market.
  • Insights about market determinants which are stimulating the global leukemia therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astellas
  • Celgene
  • Eisai
  • Innate Pharma
  • Novartis
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. by Segments
1.2.2. by Geography
1.2.3. by Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Pipeline Analysis
2.3. Key Leukemia Therapies
2.3.1. Chemotherapy
2.3.2. Stem Cell Transplant
2.3.3. Radiation Therapy
2.3.4. Targeted Therapy
2.3.5. Watchful Waiting
2.3.6. Supportive Therapy
2.3.7. Others
2.4. Analyst Insights & Current Market Trends
2.4.1. Key Findings
2.4.2. Recommendation
2.4.3. Conclusion
2.5. Regulations
2.5.1. United States
2.5.2. European Union
2.5.3. China
2.5.4. India
2.5.5. Rest of the World

3. Market Determinant
3.1. Motivators
3.1.1. Fda Nod To Leukemia Drugs Are Driving the Market
3.1.2. Success of R&D In Leukemia Therapeutic and Drugs
3.1.3. Advancement In Cancer Therapeutics To Boost Global Leukemia Therapeutic Market
3.1.4. Rise In Adoption of Personalized Medicine In the Global Leukemia Therapeutic Market
3.1.5. Increase In Incidence and Prevalence Rate of Leukemia Diseases
3.2. Restraints
3.2.1. High Cost of Leukemia Therapeutics Is a Concern
3.2.2. Less Popular In Emerging and Under Developed Countries
3.3. Opportunities
3.3.1. Rise In Elderly Population Across the Globe
3.3.2. Successful Clinical Trials of Leukemia Drugs
3.3.3. Investment From Government and Private Players

4. Market Segmentation
4.1. Leukemia Therapeutics Market by Type
4.1.1. Acute Myeloid Leukemia
4.1.2. Chronic Myeloid Leukemia
4.1.3. Acute Lymphocytic Leukemia
4.1.4. Chronic Lymphocytic Leukemia
4.2. Leukemia Therapeutics Market by Drugs Type
4.2.1. Acute Lymphoblastic Leukemia Drugs
4.2.1.1. Asparaginase Drug
4.2.1.2. Clofarabine Drug
4.2.1.3. Daunorubicin Drug
4.2.1.4. Doxorubicin Drug
4.2.1.5. Methotrexate Drug
4.2.1.6. Nelarabine Drug
4.2.1.7. Corticosteroids Drug
4.2.1.8. Other Acute Myeloid Leukemia Drug
4.2.2. Myelogenous Leukemia Drug
4.2.2.1. Cytarabine Drug
4.2.2.2. Daunorubicin Drug
4.2.2.3. Idarubicin Drug
4.2.2.4. Mitoxantrone Drug
4.2.3. Chronic Lymphocytic Leukemia Drug
4.2.3.1. Alemtuzumab Drug
4.2.3.2. Bendamustine Hydrochloride Drug
4.2.3.3. Ibrutinib Drug
4.2.3.4. Other Drugs
4.2.4. Acute Promyelocytic Leukemia Drug
4.2.4.1. Arsenic Trioxide Drug
4.2.4.2. Idarubicin Drug
4.2.4.3. Other Drugs
4.2.5. Other Drugs
4.2.5.1. Dacogen Drug
4.2.5.2. Omapro Drug
4.2.5.3. Cladribine Drug
4.2.5.4. Topotecan Cladribine Drug
4.2.5.5. Methotrexate Drug
4.2.5.6. Other Drugs

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.1.3. Rest of North America
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.4. Rest of the World

7. Company Profiles
7.1. Abbott Laboratories
7.2. Agios Pharmaceuticals
7.3. Ambit Biosciences
7.4. Astellas
7.5. Biogen
7.6. Bristol-Myers Squibb
7.7. Celgene
7.8. Cephalon
7.9. Clavis Pharma Asa
7.10. Eisai
7.11. Genzyme
7.12. Glaxosmithkline Plc
7.13. Innate Pharma
7.14. Johnson & Johnson
7.15. Merck & Co.
7.16. Novartis
7.17. Pfizer
7.18. Roche Holdings Ag
7.19. Sunesis Pharmaceuticals Inc
7.20. Talon Therapeutics Inc
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Agios Pharmaceuticals
  • Ambit Biosciences
  • Astellas
  • Biogen
  • Bristol-Myers Squibb
  • Celgene
  • Cephalon
  • Clavis Pharma Asa
  • Eisai
  • Genzyme
  • Glaxosmithkline Plc
  • Innate Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche Holdings Ag
  • Sunesis Pharmaceuticals Inc
  • Talon Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll